Devyser has received IVDR approval for its non-invasive fetal RHD screening product. This marks the first approval of a Class D product, the highest risk class under the new,…
Devyser Diagnostics AB has appointed a Nomination Committee in preparation for the 2025 Annual General Meeting. The Nomination Committee's task is to present proposals to the meeting…
“It is very gratifying to see the impact that we are having in the field of diagnostics. I have just returned from the ASHI event, a major transplantation conference in the US, and it is…
Devyser has entered an agreement with Thermo Fisher Scientific to collaborate on obtaining U.S. Food and Drug Administration (FDA) approval for One Lambda™ Devyser Accept cfDNA, their…
Devyser has achieved a significant regulatory milestone with its first market registration from China’s National Medical Products Administration (NMPA) for Devyser Compact, an…
Devyser invites investors, analysts and media to a Capital Markets Day on Monday, November 25, 2024 at the company's headquarters in Årsta, Stockholm.
The program will include…
On Wednesday, October 30 at 09:00 a.m. CET, Devyser Diagnostics AB will host an online presentation of its Q3 2024 report (which will have been published earlier on October 30 at 07:30…
Devyser Diagnostics AB (publ) today announces that the company has terminated the liquidity guarantee agreement with Carnegie Investment Bank. The agreement expires on November 29,…
Devyser’s post-transplant products will be featured in 7 posters at the upcoming American Society of Histocompatibility and Immunogenetics (ASHI) meeting at Anaheim California in October,…
“Devyser continued to report high sales growth in the second quarter. Organic growth compared with the same quarter of last year amounted to 41 percent in SEK. We won several large…
